SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide

Completed · Phase 3

Conditions studied: Neutropenia, Breast Cancer

In brief

The purpose of this study is to compare the efficacy of SPI-2012 versus pegfilgrastim in participants with early-stage breast cancer receiving docetaxel and cyclophosphamide (TC) as measured by the duration of severe neutropenia (DSN).

Key facts

Study ID
NCT02953340
Run by
Spectrum Pharmaceuticals, Inc
People needed
237
Starts
2017-05-10
Expected to finish
2019-05-06
Last updated by the study team
2022-03-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.